How does CVD prevalence vary across SARS, MERS, and COVID-19?

  • Liu Y & al.
  • J Am Heart Assoc
  • 15 Jul 2020

  • curated by Emily Willingham, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Cardiovascular diseases (CVDs) vary among the coronavirus diseases SARS, MERS, and COVID-19, according to this pooled meta-analysis.
  • MERS was linked to higher proportions of hypertension, unspecified cardiac disease, and diabetes.
  • COVID-19 is linked to more hypertension than SARS.

Why this matters

  • These variable associations with the different coronaviruses could help elucidate what drives different outcomes among their corresponding diseases.

Key results

  • 22 studies: 12 COVID-19 (n=51,268), 4 SARS (n=1608), 6 MERS (n=597).
  • CVD comorbidity proportions (95% CIs) by viral disease:
    • COVID-19:
      • Hypertension: 17.1% (13.2%-20.9%).
      • Cardiac disease: 4.5% (3.6%-5.5%).
      • Diabetes: 8.5% (5.5%-11.4%).
    • SARS:
      • Hypertension: 4.5% (2.0%-7.0%).
      • Cardiac disease: 2.1% (0.6%-3.7%).
      • Diabetes: 3.7% (1.0%-6.4%).
    • MERS:
      • Hypertension: 30.3% (18.3%-42.2%).
      • Cardiac disease: 20.9% (10.7%-31.1%).
      • Diabetes: 45.4% (27.3%-63.5%).

Study design

  • Meta-analysis.
  • Funding: Nature Science Foundation of China.

Limitations

  • Widely varying number of included participants.
  • Definition of “cardiac disease” may have varied.